Document is current

Any future updates will be listed below

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

Crossref DOI link: https://doi.org/10.1186/s40425-017-0279-5

Published Online: 2017-09-19

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark